Enzyme Family Plays Role in Alzheimer's
Posted on: Monday, 20 June 2005, 18:40 CDT
The route to a treatment for Alzheimer's disease may have become more straightforward with the discovery that a key enzyme known to have a major role in this disease is in fact part of a family of enzymes. Only some family members play a role in the progression of this brain-wasting illness, new research at the University of Toronto has found.
"It was previously thought that an enzyme called gamma-secretase contributed to the development of protein deposits in the Alzheimer's brain. This study shows that this enzyme is more accurately described as a family of enzymes, each with its own specialization," explains Professor David Westaway of U of T's Centre for Research in Neurodegenerative Diseases and senior author of a paper in the June 21 issue of the Proceedings of the National Academy of Sciences.
Gamma-secretase enzymes generate toxic molecules called amyloid-beta peptides. These peptides produce deposits called amyloid plaques, the brain lesions that are a defining feature of Alzheimer's disease. If scientists can stop these enzymes from working, they will be able to stop their resulting toxic molecules from forming in the brain. Complicating the situation is the fact that the gamma-secretase enzyme was also thought to be involved in healthy functioning of other tissues; therefore, therapies would have to inhibit the negative effects while maintaining the normal functioning of other cells.
Westaway and his research colleagues used genetically-engineered mice to show that toxic activity of gamma-secretase could be separated from its other benign activities.
"This finding provides hope that Alzheimer's treatments can be developed that reduces toxic activity of certain gamma-secretases while still maintaining the beneficial activities of other family members," says Peter Mastrangelo, a research associate in Westaway's lab and first author of the paper.
On the World Wide Web:
Related Articles
- EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator
- Prize4Life and the Alzheimer Research Forum Announce Launch of New Web-Portal for ALS Research
- Fisher Center for Alzheimer's Research Foundation Names Kent Karosen to Serve as President and CEO
- Family Consent Supported By Most In Alzheimer's Research
- Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted By TorreyPines Therapeutics
- Feds Charge Alzheimer's Researcher
- Webcast Alert: Top Scientists Offer Predictions on Alzheimer's Research and Impact of Alzheimer's Disease on Society
- The Fisher Center for Alzheimer's Research Foundation Celebrates 10 Year Anniversary
- 9th Annual Memory Ride for Alzheimer's Research
User Comments (0)

RSS Feeds